Trial Profile

A Pivotal phase III trial of SPN-604 (Oxtellar XR) for Bipolar disorders

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 05 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxcarbazepine (Primary)
Indications Bipolar disorders
Focus Registrational; Therapeutic Use
Sponsors Supernus Pharmaceuticals

Most Recent Events

25 Feb 2020 According to Supernus Pharmaceuticals media release, the Company expects enrollment in the trial to continue through 2021.
05 Nov 2019 According to Supernus Pharmaceuticals media release, this trial has been initiated in the fourth quarter of 2019.
05 Nov 2019 Status changed from planning to recruiting, according to Supernus Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com